Get Premium to unlock powerful stock data
MEI Pharma Inc logo

MEI Pharma Inc

$ 0.49 +0.0196 (+4.21%) 10:08 PM EST
P/E:
At Loss
P/B:
0.82
Market Cap:
$ 64.58M
Enterprise V:
$ -115.94M
Volume:
1.83M
Avg Vol (2M):
8.56M
Also Trade In:
Volume:
1.83M
Market Cap $:
64.58M
PE Ratio:
At Loss
Avg Vol (2-Month):
8.56M
Enterprise Value $:
-115.94M
PB Ratio:
0.82
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

MEI Pharma Inc
NAICS : 325412 SIC : 2834
11455 El Camino Real, Suite 250, San Diego, CA, USA, 92130
Description
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Name Current Vs Industry Vs History
Cash-To-Debt 23.69
Equity-to-Asset 0.37
Debt-to-Equity 0.1
Debt-to-EBITDA -0.13
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -1.7
Distress
Grey
Safe
Beneish M-Score -3.24
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 42.31
9-Day RSI 39.39
14-Day RSI 36.12
6-1 Month Momentum % -79.5
12-1 Month Momentum % -80.68

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.58
Quick Ratio 6.58
Cash Ratio 6.09
Days Sales Outstanding 82.69
Days Payable 5805.57

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -16.9

Financials (Next Earnings Date:2022-09-02 Est.)

MEIP's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:MEIP

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Performance
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 44.143
EPS (TTM) ($) -0.61
Beta 1.11
Volatility % 84.37
14-Day RSI 36.12
14-Day ATR ($) 0.059569
20-Day SMA ($) 0.52887
12-1 Month Momentum % -80.68
52-Week Range ($) 0.4493 - 3.55
Shares Outstanding (Mil) 132.99

Piotroski F-Score Details

Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

MEI Pharma Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More